The PCSK9 inhibitors alirocumab and evolocumab dramatically reduce low-density lipoprotein cholesterol levels—by about 60%—and outcomes studies show that they have the potential to improve morbidity and mortality from atherosclerotic cardiovascular disease. Usually used in combination with statins, these self-administered injectable agents (given once or twice monthly) are already changing standards of care for dyslipidemia.
After completing this activity, participants should be better able to:
- Maximize ASCVD risk reduction using agents beyond, or in addition to, statins
- Review current guideline recommendations in order to select dyslipidemia treatment targets according to patient preferences and individual factors, including level of overall ASCVD risk
- Develop patient-centered approaches to improve adherence and access to lipid-lowering therapy
- Physician Assistants
- Nurse Practitioners
Aout the Presenter:
Dr. Douglas Jacoby is a cardiologist in Philadelphia, Pennsylvania and is affiliated with multiple hospitals in the area, including Cape Regional Medical Center and Hospitals of the University of Pennsylvania-Penn Presbyterian. He received his medical degree from Harvard Medical School and has been in practice between 11-20 years. Dr. Jacoby accepts several types of health insurance, listed below. He is one of 13 doctors at Cape Regional Medical Center and one of 95 at Hospitals of the University of Pennsylvania-Penn Presbyterian who specialize in Cardiology.
You will receive an email with login information and handouts (presentation slides) that you can print and share to all participants at your location.
Operating System: Windows any version preferably above Windows Vista & Mac any version above OS X 10.6
Internet Speed: Preferably above 1 MBPS
Headset: Any decent headset and microphone which can be used to talk and hear clearly
Can’t Listen Live?
No problem. You can get access to On-Demand webinar. Use it as a training tool at your convenience.
For more information you can reach out to below contact:
Toll-Free No: 1-302-444-0162